Physician profile
Timothy Reisner
NPI 1457703753
$1,034.52
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $385 · 2021: $460.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.07 | 2019-2021 | |
| Lilly USA, LLC | $203.95 | 2020-2021 | |
| Corcept Therapeutics | $94.42 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.39 | 2021 | |
| Tandem Diabetes Care, INC. | $41.31 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $38.03 | 2021 | |
| Dexcom, INC. | $35.70 | 2020-2021 | |
| Radius Health, INC. | $31.84 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $22.06 | 2021 | |
| Shire North American Group INC | $20.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.61 | 2019 | |
| Horizon Therapeutics Plc | $17.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Reisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.